Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309–16.
Szafarowski T, Szczepanski MJ. Cancer stem cells in head and neck squamous cell carcinoma. Otolaryngol Pol. 2014;68(3):105–11.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer. 2006;107(2):337–44.
Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127–48.
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53(1):615–27.
Li JZ, Gao W, Chan JY, Ho WK, Wong TS. Hypoxia in head and neck squamous cell carcinoma. ISRN Otolaryngol. 2012 Oct 16;2012:708974.
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27.
Lee DJ, Kang SW. Reactive oxygen species and tumor metastasis. Mol Cells. 2013;35(2):93–8 (Retracted article).
Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009;69(24):9245–53.
Shanbhag VL. Understanding cancer stem cells in head and neck cancer: an insight from oral medicine point of view. Oncobiol Targets. 2015;2:24–8.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci. 2007;104(3):973–8.
Garg M. Potential therapeutic applications of microRNAs in response to DNA damage in cancer stem cells.J. Stem Cells. 2011;6(2):51–65.
Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, et al. MicroRNAs and genomic instability. Semin Cancer Biol. 2007;17(1):65–73.
Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M. Regulation of microRNA expression: the hypoxic component. Cell Cycle. 2007;6(12):1426–31.
Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. Hsa-Mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116(9):2148–58.
Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: The master hypoxamir. Microcirculation. 2012;19(3):215–23.
Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules. 2015;20(10):18886–906.
Lin PY, Yu CH, Wang JT, Chen HH, Cheng SJ, Kuo MY, Chiang CP. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 2008;37(1):18–25.
de Almeida Chuffa LG, Fioruci BA, Seiva FRF. Melatonin and their protective role on oxidative cell damage: interplay between oxidative stress and tumorigenesis. In: Castroviejo DA, Rusanova I, Escames G, editors. New Developments in Melatonin Research: Spain, Nova Publishers; 2013. p. 121–38.
Kim JH, Park SG, Song SY, Kim JK, Sung JH. Reactive oxygen species responsive miR-210 regulates proliferation and migration of adipose derived stem cells via PTPN2. Cell Death Dis. 2013;4:e588.
Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56(3):248–53.
Shah MY, Pan X, Fix LN, Farwell MA, Zhang B. 5-fluorouracil drug alters the microrna expression profiles in MCF-7 breast cancer cells. J Cell Physiol. 2011;226(7):1868–78.
Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006;66(20):9789–93.
Gonçalves N, Colombo J, Lopes JR, Gelaleti GB, Moschetta MG, Sonehara NM, et al. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PLoS One. 2016;11(3):e0150407.
Koçak N, Dönmez H, Yildirim İH. Effects of melatonin on apoptosis and cell differentiation in MCF-7 derived cancer stem cells. Cell Mol Biol (Noisy-le-grand). 2018;64(12):56–61.
Akbarzadeh M, Movassaghpour AA, Ghanbari H, Kheirandish M, Maroufi NZ, Rahbarghazi R, et al. c. Sci Rep. 2017; 7: 17062.
Ullmann P, Qureshi-Baig K, Rodriguez F, Ginolhac A, Nonnenmacher Y, Ternes D, et al. Hypoxia-responsive miR210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production. Oncotarget. 2016;7(40):65455–70.
Tang T, Yang Z, Zhu Q, Wu Y, Sun K, Alahdal M, et al. Up-regulation of miR-210 induced by a hypoxic microenvironment promotes breast cancer stem cell metastasis, proliferation, and self-renewal by targeting E-cadherin. FASEB J. 2018:fj201801013R.
Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, et al. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009;61(4):413–29.
Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9(11):4227–39.
Zeeberg BR, Kohn KW, Kahn A, Larionov V, Weinstein JN, Reinhold W, et al. Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples. PLoS One. 2012;7(7):e40062.